Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Apr 4;4(7):1052–1060. doi: 10.1158/1940-6207.CAPR-11-0067

Figure 1. P-S alone and in combination with DFMO inhibits colon cancer growth in a xenograft model.

Figure 1

A- Chemical structure of phospho-sulindac (P-S; OXT-328). B-D- HT-29 cells (2 × 106) were injected subcutaneously into the right and left flank of nude mice. Drug administration was started one week prior to tumor injection. Animals were gavaged with 100 mg/kg P-S once a day for 18 days. DFMO 2% (w/v) was dissolved in water. B- Body weight progression over the course of the study for vehicle control (◇), P-S (■), DFMO (▲) and P-S/DFMO (○) treated mice. No significant differences in body weight were observed among the various groups. C- Tumor volume growth over time for vehicle control (◇), P-S (■), DFMO (▲) and P-S/DFMO (○) treated mice. *Significantly different from all the other groups (p<0.01, one way ANOVA test). #Significantly different compared to P-S/DFMO group (p<0.05, one way ANOVA test). D- Tumor mass of the dissected tumors. Mean tumor size in mice treated with P-S, DFMO and the combination of the two was smaller than that of vehicle. All values: mean±SEM, *p<0.05.